AVIR
Atea Pharmaceuticals, Inc.
Next earnings Aug 5, 2026 · consensus $-0.57 EPS
Last earnings +1.7% on 2026-05-12
$4.49
▲ 0.00%$4.49▲ +35.24%
over 1Y
L $2.82EODHDH $6.15
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+2.3%
1M-1.3%
3M-12.3%
YTD+29.0%
1Y+35.2%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Revenue grew 622.5% YoY; but unprofitable (net margin -45.1%).
Revenue (FY2021) $351M · FY2021
Atea Pharmaceuticals, Inc. shows $351M in FY2021 revenue (+622.5% YoY), a -45.1% net margin, and -57.5% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $351M | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $138M | -$131M | -$164M | -$193M | -$181M |
| Net income | $121M | -$116M | -$136M | -$168M | -$158M |
| Diluted EPS | $1.37 | -$1.39 | -$1.63 | -$2.00 | -$1.94 |
| Net margin | 34.5% | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$262M
EV / EBITDA—
EV / Sales0.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-44.3%
FCF yield-37.5%
Quality & risk
ROIC (est.)-51.9%
Free cash flow-$134M
Total debt—
Net cash$95.7M
Altman Z-Score3.33 safe
Piotroski F-Score3/7
Capital returns
Buyback yield7.1%
Dividend yield (est.)—
Shareholder yield7.1%
Shares Δ YoY-6.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗4Period ending 2026-06-182026-06-23open ↗8-KPeriod ending 2026-06-182026-06-22open ↗4/APeriod ending 2026-05-182026-05-21open ↗4Period ending 2026-05-182026-05-20open ↗10-QPeriod ending 2026-03-312026-05-12open ↗
Frequently asked
- Is Atea Pharmaceuticals, Inc. (AVIR) a buy?
- AVIR currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 622.5% YoY; but unprofitable (net margin -45.1%).
- What is Atea Pharmaceuticals, Inc.'s quality score?
- AVIR scores 59.58823529411764/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001593899, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 7:17:05 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.